Cargando…
Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease
Pompe disease is caused by the deficiency of lysosomal acid α-glucosidase (GAA). It is expected that gene therapy to replace GAA with adeno-associated virus (AAV) vectors will be less effective early in life because of the rapid loss of vector genomes. AAV2/8-LSPhGAA (3 × 10(10) vector genomes [vg]/...
Autores principales: | Han, Sang-oh, Li, Songtao, McCall, Angela, Arnson, Benjamin, Everitt, Jeffrey I., Zhang, Haoyue, Young, Sarah P., ElMallah, Mai K., Koeberl, Dwight D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938806/ https://www.ncbi.nlm.nih.gov/pubmed/31909086 http://dx.doi.org/10.1016/j.omtm.2019.11.020 |
Ejemplares similares
-
Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017) -
Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019) -
Macroglossia, Motor Neuron Pathology, and Airway Malacia Contribute to Respiratory Insufficiency in Pompe Disease: A Commentary on Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases
por: McCall, Angela L., et al.
Publicado: (2019) -
The Respiratory Phenotype of Pompe Disease Mouse Models
por: Fusco, Anna F., et al.
Publicado: (2020) -
Glycogen accumulation in smooth muscle of a Pompe disease mouse
model
por: McCall, Angela L., et al.
Publicado: (2021)